速递|印度仿制药巨头已获司美格鲁肽批文!本地GLP-1药物市场已达100亿卢比

GLP1减重宝典
Jan 25

整理 | GLP1减重宝典内容团队随着2026年3月专利大限临近,全球GLP-1市场最激烈的一场战役,正在印度悄然成型。过去三年,在全球医药产业中几乎没有哪个赛道像GLP-1类减肥与降糖药物这样持续制造财富神话。从欧美到亚洲,司美格鲁肽迅速完成从处方药到社会议题的跃迁,而在这场浪潮之下,被称为世界药房的印度,正酝酿一次足以改写价格体系的系统性冲击。最新的法院动向显示,随着诺和诺德核心专利进入倒计时...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10